,Nine Months Ended September 30,Nine Months Ended September 30,Nine Months Ended September 30,Nine Months Ended September 30,Nine Months Ended September 30,Nine Months Ended September 30,Nine Months Ended September 30,Nine Months Ended September 30
,Cumulative Foreign Currency Translation Adjustments,Cumulative Foreign Currency Translation Adjustments,Net Actuarial Losses and Prior Service Costs and Credits,Net Actuarial Losses and Prior Service Costs and Credits,Cumulative Unrealized Gains on Marketable Equity Securities,Cumulative Unrealized Gains on Marketable Equity Securities,Cumulative Gains on Derivative Instruments Designated as Cash Flow Hedges,Cumulative Gains on Derivative Instruments Designated as Cash Flow Hedges
(in millions),2014,2013,2014,2013,2014,2013,2014,2013
"Balance at December 31, 2013 and 2012",(718),(79),(1312),(3596),13,31,5,50
Separation of AbbVie (a),—,(308),—,1451,—,—,—,8
Other comprehensive income (loss) before Reclassifications,(1053),(480),—,(77),4,17,66,(8)
Amounts reclassified from accumulated other comprehensive income (b),—,—,44,82,(16),(21),(8),(26)
Net current period comprehensive income (a),(1053),(480),44,5,(12),(4),58,(34)
Balance at September 30,(1771),(867),(1268),(2140),1,27,63,24